However, targeted therapies like Bruton’s tyrosine kinase (BTK) inhibitors and BCL-2 inhibitors are emerging as novel treatment options, particularly in MCL and CLL [3, 4, 6]. The gene discussed is BTK; the disease is B-cell chronic lymphocytic leukemia.